Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke-Reference-Cited by-同舟云学术

Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke

Published:2016-10-01 Issue:1 Volume:43 Page:112-116
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Seiffge David J.,Traenka Christopher,Polymeris Alexandros,Hert Lisa,Fisch Urs,Peters Nils,De Marchis Gian Marco,Guzman Raphael,Nickel Christian H.,Lyrer Philipp A.,Bonati Leo H.,Tsakiris Dimitrios,Engelter Stefan

Funder

Schweizerische Herzstiftung

Universität Basel

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-016-1431-7.pdf

Reference16 articles.

1. Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet 383:955–962

2. Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294

3. Steiner T, Bohm M, Dichgans M et al (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 102:399–412

4. Rizos T, Herweh C, Jenetzky E et al (2009) Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 40:3547–3551

5. Rizos T, Jenetzky E, Herweh C et al (2010) Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Ann Neurol 67:788–793

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calibration-free electrochemical sensor to monitor factor-Xa inhibitors at the point-of-care anticoagulation therapy;Talanta;2024-04

2. Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy;Clinical Pharmacokinetics;2024-03

3. Management of patients with proximal femur fractures under DOACs;European Journal of Trauma and Emergency Surgery;2024-02-24

4. Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation;Cardiovascular Drugs and Therapy;2023-08-05

5. Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study;Research and Practice in Thrombosis and Haemostasis;2023-07